Literature DB >> 32858074

Hypoxia-activated ROS burst liposomes boosted by local mild hyperthermia for photo/chemodynamic therapy.

Xiang-Long Tang1, Zhen Wang2, Yun-Yang Zhu2, Hong Xiao3, Yong Xiao2, Sheng Cui4, Ben-Lan Lin4, Kun Yang5, Hong-Yi Liu6.   

Abstract

Single reactive oxygen species (ROS)-mediated therapy, photodynamic therapy (PDT) or chemodynamic therapy (CDT) is severely hindered in hypoxic solid tumor. Herein, to address the urgent challenge, a hypoxia-activated ROS burst liposome has been fabricated to achieve synergistic PDT/CDT that is initiated by the structural dissociation of poly(metronidazole) liposome in hypoxic tumor microenvironment (TME). The therapeutic enhancement of our ROS-blasting treatment is simultaneously regulated by external light-initiated PDT and endogenous iron oxide nanoclusters-triggered CDT, which is synergistically boosted and amplified by localized mild hyperthermia under 808/660 nm coirradiation. More importantly, in vitro and in vivo experiments demonstrate that electron-affinic poly(aminoimidazole) product from hypoxia-responsive transition of poly(metronidazole) polymers could efficiently enhance hypoxic cell apoptosis and induce solid tumor ablation. Thus, this work offers a potential hypoxia-activated ROS burst-PDT/CDT strategy with a superior antitumor efficacy, highlighting a promising clinical application.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemodynamic therapy; Hypoxia-responsive; Iron oxide clusters; Photodynamic therapy; Reactive oxygen species

Year:  2020        PMID: 32858074     DOI: 10.1016/j.jconrel.2020.08.035

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment.

Authors:  Shihui Bao; Hailun Zheng; Jinyao Ye; Huirong Huang; Bin Zhou; Qing Yao; Guangyong Lin; Hailin Zhang; Longfa Kou; Ruijie Chen
Journal:  Front Pharmacol       Date:  2021-03-19       Impact factor: 5.810

Review 2.  Nanomedicine potentiates mild photothermal therapy for tumor ablation.

Authors:  Zijun Jiang; Tianyi Li; Hao Cheng; Feng Zhang; Xiaoyu Yang; Shihao Wang; Jianping Zhou; Yang Ding
Journal:  Asian J Pharm Sci       Date:  2021-10-15       Impact factor: 6.598

3.  The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors.

Authors:  Hua Zhu; Xinyao Hu; Shi Feng; Zhihong Jian; Ximing Xu; Lijuan Gu; Xiaoxing Xiong
Journal:  Oxid Med Cell Longev       Date:  2022-01-17       Impact factor: 6.543

Review 4.  Lipid-based nanoparticles for photosensitive drug delivery systems.

Authors:  Gayong Shim; Sieon Jeong; Jung Leem Oh; Yeongseon Kang
Journal:  J Pharm Investig       Date:  2022-01-06

Review 5.  Tumor microenvironment-responsive fenton nanocatalysts for intensified anticancer treatment.

Authors:  Yandong Wang; Fucheng Gao; Xiaofeng Li; Guiming Niu; Yufei Yang; Hui Li; Yanyan Jiang
Journal:  J Nanobiotechnology       Date:  2022-02-05       Impact factor: 10.435

6.  Hollow Mesoporous CeO2-Based Nanoenzymes Fabrication for Effective Synergistic Eradication of Malignant Breast Cancer via Photothermal-Chemodynamic Therapy.

Authors:  Huaxin Tan; Yongzhen Li; Jiaying Ma; Peiyuan Wang; Qiaoling Chen; Lidan Hu
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.